跳至主要内容
临床试验/NCT05046093
NCT05046093已完成不适用

Clinical Outcomes of Cryobiopsy for Peripheral Pulmonary Lesions - A Prospective Pilot Study

Pusan National University Hospital2 个研究点 分布在 1 个国家目标入组 50 人开始时间: 2021年12月1日最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
50
试验地点
2
主要终点
Diagnostic yield based on pathologic diagnosis

研究概览

简要总结

As the former radial endobronchial ultrasound (R-EBUS) guided transbronchial forcep biopsy of peripheral pulmonary nodules has some limitations, the purpose of this study is to investigate a novel biopsy technique, transbronchial cryobiopsy, in patients with peripheral pulmonary nodules.

详细描述

This is a prospective, single arm, open label trial to assess the diagnostic accuracy and safety of the transbronchial cryobiopsy in patients with peripheral pulmonary nodule using a 1.1mm cryoprobe, combined with bronchoscope (with/without guide sheath), R-EBUS, virtual bronchoscopy navigation, and fluoroscopy.

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Diagnostic
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Patient with peripheral lung nodule less than 30mm on CT scan referred for biopsy
  • Written informed consent after participant's information

排除标准

  • Central lesion (visible on bronchoscope) or presence of metastatic lymph node (not requiring radial EBUS)
  • Pure GGO lesion
  • Patients at increased risk of bleeding
  • Cannot stop agents such as antiplatelet agent or anticoagulant therapy
  • Coagulopathy: Thrombocytopenia (< 100,000/mm3) or prolonged PT (INR > 1.5)
  • Patient with existing or risk of pulmonary and cardiovascular decompensation
  • Intolerance to sedation
  • Vulnerable groups such as pregnant woman, breast feeding, etc.
  • Previously diagnosed cancer patient who needs re-biopsy for genetic susceptibility

结局指标

主要结局

Diagnostic yield based on pathologic diagnosis

时间窗: up to 6 months

Diagnostic yield based on pathologic diagnosis is defined as percentage of definitive pathological diagnosis by transbronchial cryobiopsy. If the bronchoscopic procedure fails to diagnose malignancy, the gold standard will be the results of additional procedures such as repeated bronchoscopic biopsy, percutaneous needle aspiration, surgical biopsy, or CT follow-up without any invasive procedure.

次要结局

  • Diagnostic yield based on clinical diagnosis(up to 6 months)
  • Adverse events(up to 1 week)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (2)

Loading locations...

相似试验